Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
KRYS's Cash-to-Debt is ranked higher than
61% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. KRYS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
KRYS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.04  Med: No Debt Max: No Debt
Current: No Debt
1.04
No Debt
Altman Z-Score: 93.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -17.52
KRYS's ROE % is ranked higher than
59% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. KRYS: -17.52 )
Ranked among companies with meaningful ROE % only.
KRYS' s ROE % Range Over the Past 10 Years
Min: -397.92  Med: -214.88 Max: -17.52
Current: -17.52
-397.92
-17.52
ROA % -17.07
KRYS's ROA % is ranked higher than
56% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. KRYS: -17.07 )
Ranked among companies with meaningful ROA % only.
KRYS' s ROA % Range Over the Past 10 Years
Min: -52.7  Med: -41.5 Max: -17.07
Current: -17.07
-52.7
-17.07
ROC (Joel Greenblatt) % -1977.63
KRYS's ROC (Joel Greenblatt) % is ranked lower than
80% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. KRYS: -1977.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KRYS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2294.23  Med: -1411.7 Max: -529.17
Current: -1977.63
-2294.23
-529.17
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KRYS's 30-Y Financials

Financials (Next Earnings Date: 2019-05-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

KRYS Guru Trades in

KRYS Guru Trades in

KRYS Guru Trades in

Q3 2018

KRYS Guru Trades in Q3 2018

Jim Simons 50,700 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:KRYS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Krystal Biotech Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:LPTX, NAS:EIGR, OSTO:MVIR B, OTCPK:NWBO, OTCPK:CYDY, TPE:1733, NAS:KALV, FRA:PB9, XPAR:GNRO, OSL:TRVX, NAS:OPHT, ROCO:4193, ASX:MDC, TSE:4572, TSX:APS, LSE:DDDD, XMCE:ORY, NAS:BLRX, NAS:MACK, NAS:CDTX » details
Traded in other countries:4KB.Germany,
Headquarter Location:USA
Krystal Biotech Inc is a biopharmaceutical company. It uses gene therapy treatments for patients suffering from rare debilitating disorders.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is a gene therapy company dedicated to developing and commercialising novel treatments for patients suffering from dermatological diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.

Ratios

vs
industry
vs
history
PB Ratio 4.75
KRYS's PB Ratio is ranked higher than
54% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. KRYS: 4.75 )
Ranked among companies with meaningful PB Ratio only.
KRYS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 29.16
Current: 4.75
0
29.16
EV-to-EBIT -29.71
KRYS's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. KRYS: -29.71 )
Ranked among companies with meaningful EV-to-EBIT only.
KRYS' s EV-to-EBIT Range Over the Past 10 Years
Min: -95.88  Med: 0 Max: 0
Current: -29.71
-95.88
0
EV-to-EBITDA -30.01
KRYS's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. KRYS: -30.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
KRYS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -96.06  Med: 0 Max: 0
Current: -30.01
-96.06
0
Current Ratio 27.57
KRYS's Current Ratio is ranked higher than
99% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. KRYS: 27.57 )
Ranked among companies with meaningful Current Ratio only.
KRYS' s Current Ratio Range Over the Past 10 Years
Min: 6.73  Med: 50.44 Max: 105.46
Current: 27.57
6.73
105.46
Quick Ratio 27.57
KRYS's Quick Ratio is ranked higher than
99% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. KRYS: 27.57 )
Ranked among companies with meaningful Quick Ratio only.
KRYS' s Quick Ratio Range Over the Past 10 Years
Min: 6.73  Med: 50.44 Max: 105.46
Current: 27.57
6.73
105.46

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.94
KRYS's Price-to-Net-Cash is ranked higher than
72% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. KRYS: 4.94 )
Ranked among companies with meaningful Price-to-Net-Cash only.
KRYS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.75  Med: 2.22 Max: 5.14
Current: 4.94
1.75
5.14
Price-to-Net-Current-Asset-Value 4.89
KRYS's Price-to-Net-Current-Asset-Value is ranked higher than
71% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. KRYS: 4.89 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KRYS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.74  Med: 2.2 Max: 5.1
Current: 4.89
1.74
5.1
Price-to-Tangible-Book 4.74
KRYS's Price-to-Tangible-Book is ranked higher than
62% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. KRYS: 4.74 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KRYS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.74  Med: 2.19 Max: 4.93
Current: 4.74
1.74
4.93
Earnings Yield (Greenblatt) % -3.36
KRYS's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. KRYS: -3.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KRYS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.99  Med: 0 Max: 0
Current: -3.36
-11.99
0

More Statistics

EPS (TTM) $ -0.42
Volatility55.62%
52-Week Range $8.61 - 28.75
Shares Outstanding (Mil)14.43

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $)
EBIT (Mil $) -11 -12 -17 -20
EBITDA (Mil $) -11 -12 -17 -20
EPS ($) -0.88 -0.96 -1.05 -1.27
EPS without NRI ($) -0.88 -0.96 -1.05 -1.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}